Bringing the fundamentals into focus…
Bringing the fundamentals into focus…
ZURA · against 588 other Healthcare companies listed in US-listed
Ranked #313 of 589 · scores higher than 3% of peers
Bars: peers in each 10-point band of the valuation score277 peers with a valuation score of 0–9, including ZURA · Click a bar to see the companies
Mainly because of its EBITDA yield, earnings yield and free cash flow yield, which are weaker than most Healthcare peers.
| Metric | ZURA | Peer median | Better than | Position among peers | Weight |
|---|---|---|---|---|---|
| Earnings yieldHigher is better · 577 reported | -27.8% | -4.3% | 16% | 30% | |
| EBITDA yieldHigher is better · 578 reported | -52.3% | -0.8% | 9% | 50% | |
| Free cash flow yieldHigher is better · 553 reported | -20.3% | -2.3% | 16% | 20% | |
| Book yieldHigher is better · 587 reported | 51.8% | 25.9% | 75% | Context only |
| Rank | Company | Market cap | Valuation | Overall |
|---|---|---|---|---|
| 1 | 256M USD | 98 | 80 | |
| 2 | 595M USD | 96 | 97 | |
| 2 | 433M USD | 96 | 81 | |
| 2 | 289M USD | 96 | 57 | |
| 2 | 810M USD | 96 | 69 | |
| 313 | 2.3B USD | 8 | 27 | |
| 313 | 453M USD | 8 | 6 | |
| 313 | 1.8B USD | 8 | 23 | |
| 313 | 2.5B USD | 8 | 31 | |
| 313 | 382M USD | 8 | ||
| 313 | 2.2B USD | 8 | 20 | |
| 571 | 337M USD | 0 | 33 | |
| 571 | 1.0B USD | 0 | 35 | |
| 571 | 617M USD | 0 | 28 |
Scores are sector-relative percentiles from the latest snapshot, always calculated against the whole sector: narrowing the comparison group changes who you compare with, not the scores. Missing metrics are left out and the remaining weights rescaled. How we score